BI Asset Management Fondsmaeglerselskab A S Cuts Stake in Pfizer Inc. $PFE

BI Asset Management Fondsmaeglerselskab A S lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 266,493 shares of the biopharmaceutical company’s stock after selling 33,113 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Pfizer were worth $6,636,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in PFE. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. YANKCOM Partnership purchased a new position in Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter worth $32,000. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Stock Performance

Shares of PFE opened at $26.04 on Monday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock’s 50-day simple moving average is $26.62 and its 200 day simple moving average is $26.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market capitalization of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the business posted $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays began coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective on the stock. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.